



Nanoform Finland Plc – Manager's transactions – Albert Hæggström

Nanoform Finland Plc – Manager's transactions – June 10, 2020 at 02:00 p.m. Finnish time

Manager's transaction related to Nanoform Finland Plc's CFO and member of the Board of Directors Albert Hæggström's subscription of shares in relation to the initial public offering on June 4, 2020 for which trades settled on June 8, 2020.

Nanoform Finland Plc - Managers' Transactions

Person subject to the notification requirement

Name: Haeggström Albert

Position: Member of the Board/Deputy member

Issuer: Nanoform Finland Plc

LEI: 743700JJO2NU8LBS1592

Notification type: INITIAL NOTIFICATION

Reference number: 743700JJO2NU8LBS1592_20200610102756_7

Transaction date: 2020-06-08

Venue: FIRST NORTH FINLAND (FNFI)

Instrument type: SHARE

ISIN: FI4000330972

Nature of the transaction: SUBSCRIPTION

Transaction details

(1): Volume: 30,300 Unit price: 3.45 EUR

Aggregated transactions

(1): Volume: 30,300 Volume weighted average price: 3.45 EUR

Further enquiries:

Albert Hæggström, CFO
albert.haeggstrom@nanoform.com
+358 29 370 0150

Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11

Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806

Nanoform in brief

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nanoforming services. The Company's patented and scalable Controlled Expansion of Supercritical Solutions (CESS[®]) technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform's unique technology provides novel opportunities in many value-enhancing drug delivery applications.

www.nanoform.com